IL
ILM1.XETRA Medios AG
- Market cap
- EUR 288M
- P/E
- 24.6x
- P/B
- 0.56x
- ROE
- 3.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is ILM1.XETRA undervalued?
Graham numberILM1.XETRA trades 22.1% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Medios AG fundamental analysis
No fundamental analysis for Medios AG yet.
Medios AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Medios AG
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment also includes cytostatic preparations, antibody therapies, and parenteral nutrition solutions. The International Business International covers a…
Full company profileMedios AG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Medios AG annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 133M | 254M | 328M | 517M | 627M | 1.36B | 1.61B | 1.78B | 1.88B | 2.08B | 2.15B |
| Gross Profit | 7.43M | 17.4M | 23.1M | 34.0M | 37.6M | 68.5M | 107M | 109M | 151M | 91.9M | 85.4M |
| Operating Income | -821K | 6.80M | 7.40M | 14.4M | 9.54M | 15.3M | 29.0M | 31.4M | 31.7M | 41.7M | 37.3M |
| EBITDA | -712K | 7.30M | 8.56M | 16.4M | 13.1M | 34.7M | 51.3M | 52.8M | 64.0M | 79.6M | 77.1M |
| Net Income | -3.17M | 4.13M | 4.33M | 9.76M | 5.53M | 7.40M | 18.3M | 18.8M | 12.5M | 15.4M | 17.0M |
| EPS | -0.73 | 0.32 | 0.31 | 0.65 | 0.35 | 0.37 | 0.77 | 0.79 | 0.51 | 0.61 | 0.69 |
| Balance Sheet | |||||||||||
| Total Assets | 47.9M | 61.7M | 98.4M | 117M | 195M | 524M | 576M | 595M | 934M | 903M | 919M |
| Total Liabilities | 13.8M | 16.0M | 27.9M | 34.9M | 52.1M | 130M | 128M | 126M | 424M | 389M | 395M |
| Shareholders' Equity | 32.1M | 45.7M | 70.5M | 81.6M | 142M | 394M | 448M | 469M | 510M | 514M | 524M |
| Cash & Short-term Investments | 17.1M | 16.7M | 11.8M | 15.6M | 19.8M | 168M | 79.2M | 71.0M | 106M | 81.8M | 83.2M |
| Total Debt | - | - | 203K | 6.24M | 19.2M | 49.7M | 17.9M | 17.1M | 238M | 189M | 200M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.58M | 816K | -3.14M | -449K | -38.1M | 61.5M | 37.1M | 16.4M | 73.7M | 43.0M | 16.3M |
| Capital Expenditure | 372K | 5.34M | 1.82M | 2.09M | 4.86M | 12.8M | 5.06M | 1.21M | 6.31M | 6.07M | 13.5M |
| Free Cash Flow | -1.95M | -4.53M | -4.96M | -2.54M | -43.0M | 48.7M | 32.1M | 15.1M | 67.4M | 36.9M | 2.81M |
| Ratios | |||||||||||
| ROE | -9.9% | 9.1% | 6.1% | 12.0% | 3.9% | 1.9% | 4.1% | 4.0% | 2.5% | 3.0% | 3.2% |
| ROA | -6.6% | 6.7% | 4.4% | 8.4% | 2.8% | 1.4% | 3.2% | 3.2% | 1.3% | 1.7% | 1.9% |
| Net Profit Margin | -2.4% | 1.6% | 1.3% | 1.9% | 0.9% | 0.5% | 1.1% | 1.1% | 0.7% | 0.7% | 0.8% |
| Debt to Equity | - | - | 0.00x | 0.08x | 0.13x | 0.13x | 0.04x | 0.04x | 0.47x | 0.37x | 0.38x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Medios AG dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | EUR 2.76M | 0.14 | 37.3% |
| 2020 | EUR 1.79M | 0.11 | 32.3% |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:4 on Jul 19, 2012.
Who owns Medios AG
- Insiders 19.70%
- Institutions 47.87%
- Public & others 32.43%
- Shares outstanding 25.5M
- Free float 14.3M
Medios AG company profile
- Company name
- Medios AG
- Ticker
- ILM1.XETRA
- ISIN
- DE000A1MMCC8
- Exchange
- XETRA Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 989
- Fiscal year end
- December
- Address
- Heidestrasse 9, Berlin, Germany, 10557
- Phone
- 49 30 232 5668 00
- Website
- medios.ag
About Medios AG
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment also includes cytostatic preparations, antibody therapies, and parenteral nutrition solutions. The International Business International covers all activities in the international environment from the procurement of Active Pharmaceutical Ingredients, the sterile and non-sterile drugs and the supply of public and hospital pharmacies through homecare service. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. Medios AG was founded in 2015 and is headquartered in Berlin, Germany.
Medios AG management
4- Mr. Christoph PrusseitChief Business Officer of Germany & Member of Executive Board · born 1988
- Mr. Thomas MeierCEO & Member of Executive Board · born 1968
- Mr. Stefan BauerreisCFO & Member of the Executive Board · born 1972
- Ms. Katrin Yvonne NeufferDirector Investor Relations & Communications · born 1977